Combination therapy for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of targeted radiation, an immunotherapy drug (PD-L1 inhibitor), and an anti-VEGF drug to shrink tumors and improve outcomes for people with advanced hepatocellular carcinoma that cannot be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced liver cancer (hepatocellular carcinoma) that cannot be treated with surgery.
- You should be in fairly good physical condition (able to care for yourself and be up and about more than half of your waking hours).
- Your liver function must be good enough, as measured by the Child-Pugh score (score A or B with 7 points).
- You must not have had radiation therapy to the liver area before that would overlap with the planned treatment.
- You must not have untreated active hepatitis B or C, or other serious health issues like recent heart problems, bleeding disorders, or autoimmune conditions requiring strong immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
This trial tests a combination of immunotherapy (iparomlimab/tuvonralimab), a targeted drug (bevacizumab), and radiation (SBRT) plus liver-directed chemo (HAIC) for people with advanced liver cancer (HCC) that has spread to blood vessels or a few other places. It aims to see if this approach can help control the cancer.
This trial tests a combination of targeted radiation (photon radiotherapy) with two immunotherapy drugs (tremelimumab and durvalumab) for people with intermediate or advanced liver cancer that can't be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
This trial tests a combination of moderate-dose radiation therapy and the immunotherapy drug pembrolizumab (Keytruda) for liver cancer that has spread into the main veins of the liver. It aims to see if this combination can shrink tumors and improve survival.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.